The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
    • ACR ExamRheum
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / U.S. Food and Drug Administration (FDA)

Articles tagged with "U.S. Food and Drug Administration (FDA)"

FDA Approves Amgen’s Infliximab Biosimilar Treatment

December 10, 2019 • By Reuters Staff

FDA Action on Loperamide Misuse; Plus Phase 1 Trials for BAT2506 Biosimilar Begin

November 20, 2019 • By Michele B. Kaufman, PharmD, BCGP

Trump Nominates MD Anderson Oncologist as U.S. FDA Commissioner

November 4, 2019 • By Deena Beasley

FDA Approves Ixekizumab for Treating Active Ankylosing Spondylitis

September 23, 2019 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves the Biosimilar Hadlima (Adalimumab-bwwd)

September 16, 2019 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves Upadacitinib for RA

September 2, 2019 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves AbbVie’s New Rheumatoid Arthritis Drug

August 19, 2019 • By Reuters Staff

FDA Approves Risankizumab, Adds Stronger Warning to Sleep Medications

May 29, 2019 • By Michele B. Kaufman, PharmD, BCGP

Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus

May 21, 2019 • By Michele B. Kaufman, PharmD, BCGP

IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis

May 14, 2019 • By Michele B. Kaufman, PharmD, BCGP

  • 1
  • 2
  • 3
  • …
  • 7
  • Next Page »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR/ARP Meeting Abstracts

Browse and search abstracts from the ACR/ARP Annual Meetings going back to 2012.

Visit the ACR/ARP Meeting Abstracts site »

ACR/ARP Annual Meeting

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Annual Meeting site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

This site uses cookies: Find out more.